Latest Conference Articles

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses the different standard frontline therapies for patients with chronic lymphocytic leukemia.

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.